Understanding why some people with factor XI deficiency bleed more than others
Official title: Interdisciplinary approach to elucidate modifiers of bleeding phenotype in factor XI deficiency
Funded at Univ of North Carolina Chapel Hill · NIH-11332657 · Data updated 2026-11-12
A doctor-scientist team is studying why people with low factor XI have very different bleeding risks and is looking for ways to better predict who might bleed.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | May 15, 2024 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $587,734 |
| NIH project number | 5R01HL173974-03 |
| Project ID | NIH-11332657 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with congenital FXI deficiency from well-characterized patient groups, including both bleeders and non-bleeders.
✕Less likely to help
Patients without FXI deficiency or without bleeding symptoms may not directly benefit from these findings.
What this research studies
People born with low factor XI can bleed a lot after injuries, but others with the same deficiency do not. This project uses patient blood samples to study what makes bleeding happen in FXI deficiency and to develop simple tests that predict who is at higher risk. The team combines lab tests, computational models, and analysis of real patient data to identify factors that influence bleeding. If successful, the work could lead to better, more personalized guidance for preventing bleeds in these patients.
Why it matters
Potential benefit: This research could lead to better prediction of bleeding risk and more tailored care for people with FXI deficiency, potentially reducing unnecessary treatments and improving safety.
How similar studies have gone: Previous work has shown that lab assays can differentiate bleeders from non-bleeders in FXI deficiency, supporting the approach.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Wolberg, Alisa S. — Univ of North Carolina Chapel Hill
- Study coordinator: Wolberg, Alisa S.
Related research
Other NIH-funded projects on the same topics.
-
Direct measurement of RhD sensitization after early-pregnancy bleeding
This study tests how often Rh immunoglobulin given after bleeding in early pregnancy prevents RhD sensitization in pregnant people.
-
EpiMAX: a new injectable gel that stops GI bleeding quickly and for days
A new injectable hydrogel with epinephrine-loaded microparticles is designed to plug GI bleeds and provide immediate and lasting hemostasis for about 72 hours.
-
Dynamic risk tools to prevent blood clots and bleeding in cancer patients
A new AI-based approach will predict who among people with cancer starting treatment is at higher risk for blood clots or dangerous bleeding, helping doctors tailor preventive care.
-
Bleeding and Platelet Problems in Ehlers-Danlos Syndrome
This NIH grant looks at why people with Ehlers-Danlos syndrome bleed more and how platelet function is involved, with goals that could lead to better care during surgery or emergencies.
-
Long-acting RNA therapy to control fibrinolysis and reduce bleeding
A new RNA treatment delivered in lipids aims to slow down fibrinolysis and lessen bleeding for people with bleeding disorders or severe hemorrhage.
-
Thrombosis and Bleeding Risk in Medical Inpatients
A patient-facing program to better predict who is at risk for blood clots or bleeding during and after hospital stays, and to tailor prevention accordingly.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.